Conference Banner

Leaders in Biobanking Congress 2013 - Day 1

Conference Proceeding CD Now Available
  • Speaker Presentations
  • Poster Abstracts
  • and More!

Day 1 | Day 2 | Day 3 | Biographies 

Monday, November 4

7:30 am Main Conference Registration


8:30 Welcome and Chairperson’s Opening Remarks

Brian Stemme, Project Director, BioCrossroads

8:45 The Strategic Importance of Biobanking to the Discovery and Development of New Medicines

Andrew M. DahlemAndrew M. Dahlem, Ph.D., Vice President, LRL Operations-LRL Europe, Eli Lilly and Company

This presentation will focus on the strategic necessity of collection and storage of biospecimens for the identification of new pharmaceutical targets and the delivery of the potential for tailored medicines to patients. Safe and reliable storage, dependable and reliable service providers and the factors that go into the decision to store samples in-house or through third parties will be evaluated. We will highlight how effective use and storage of biospecimens are critical for discovering and developing new medicines and for ensuring the right doses are given to the right patients to treat their unique needs.

9:25 Key Assets in the Development of Companion Diagnostics towards Personalized Medicine

Norma J NowakNorma J. Nowak, Ph.D., CSO and Founder, Empire Genomics LLC

As medicine is transformed from reactionary treatment to a health management approach, development of companion diagnostics is critical to achieving the goal of personalized medicine. Access to patient specimens is paramount, as is the data surrounding patient history and response to drug therapy. The timeframe for development of these pivotal assays is directly related to the availability of patient samples for testing, thus emphasizing the direct need for access to biobanks with appropriately stored and annotated clinical specimens. We will discuss our proprietary assays and the role biospecimens play in their development.

10:10 Coffee Break in the Exhibit Hall with Poster Viewing

10:45 Academia and Pharma: New Approaches for Bi-Directional Collaborations

Anantha ShekharAnantha Shekhar, M.D., Ph.D., Director, Indiana Clinical and Translational Sciences Institute, Indiana University School of Medicine

There is great need to translate the explosion in our fundamental understanding of biology into better therapeutics. Pharma Industry faces several challenges such as increasing cost of drug development and declining R&D productivity. Academia is challenged with declining public funding for research and lack of investor base for early stage development of therapeutics. Academic scientists are a critical source for new discovery and Pharma has deep experience in successful drug development, making it imperative that we create better models for collaborative drug discovery and development between these two worlds. This talk will discuss the current state, challenges and some solutions being tried in this area.

11:20 A Personal Story: Inner Strength

Traci RungeTraci Runge, Breast Cancer Survivor and Stem Cell Therapy Recipient

You never know who holds a key to offering something bigger in the biocommunity or medical world -- a group that is ever growing, learning and discovering. I wish to share my experiences that they may show support and encouragement in some way so that I too can be a “Part of this Village.” I found an inner strength that I didn’t know existed; when I was first diagnosed with breast cancer, I knew immediately I wanted my personal journey in some way to have an impact on others in the future. One simple phone call offering my cancerous tissue has been the catalyst for hopefully making that impact.

11:55 Close of Session

Illumnia logo small12:00 pm Luncheon Presentation: Illumina’s Biobank Solutions
Alem Taye, Market Development Specialist, Illumina It is widely accepted that genetic based information can support accurate sample stratification, fingerprinting and screening samples for known genetic variants that are relevant for specific disease areas.  This can potentially drive the development of new companion Dx tests or treatments with the ultimate goal of developing personalized medicine. Illumina has developed complete solutions with an automated workflow, together with the appropriate data analysis tools and a significant drop in running cost.    



Concurrent Tracks 

Business of Running a Biobank 

1:30 Chairperson's Opening Remarks

Beatrice Knudsen, M.D., Ph.D., Medical Director, Pathology and Laboratory Medicine, Cedars-Sinai Medical Center

1:35 Sample Acquisition and Sample Management: Still an Emerging Market

Brian ChadwickBrian Chadwick, Managing Member and Consultant, LookLeft Group LLC

Demand exceeds supply of usable biospecimens to meet research objectives. While the literature suggests there may be a billion biospecimens stored globally, numerous sample collection efforts require prospective clinical trials because commercial sale of samples is a disparate and regulatory-challenged marketplace. Commercial biobanking facilities often have too few acceptable samples "on the shelf," and protocols often require specifically targeted biospecimens, which are less available through commercial channels.

2:05 The Impact of Differing National Regulations and Policies on Multinational Trials Involving Specimen Collection

Amelia WarnerAmelia Warner, Pharm.D., President, Gentris Corporation; Founder and CEO, Global Specimen Solutions, Inc.

Complex global regulation and law for human specimen research continue to evolve as policymakers assess what tenets of ethical specimen procedures should be required for future biomedical research. This greatly impacts researchers' ability to collect and study representative specimen sets from global clinical trials. We will address current ongoing issues and discuss potential strategies to address successful global specimen collection.

2:35 Liver Disease Biobank: A Moving Target for Research and Clinical Study Integration

Anthoula Lazaris, Associate Director, HPB Transplant and Research Unit, Surgery,
McGill University Health Centre Research Institute

We are involved in a large-scale FRSQ project to study the cell biology of NAFLD and NASH at the mechanistic level using an innovative Systems Medicine approach that combines quantitative modeling and wet-lab research. We are performing (i) enhanced phenotyping of clinical samples through transcriptomics, proteomics and lipidomics, followed by (ii) high-end bioinformatics and systems analysis to identify disease biomarkers and (iii) biomarker validation through clinical cohorts. This presentation will describe our experiences in the creation of the MUHC-RI Liver Disease Biobank, where high-quality liver specimens are collected.

3:05 Selected Oral Poster Presentation: Cincinnati Children’s Heart Institute BioRepository (HIBR) for Pediatric Heart Disease

Robert B. Hinton, M.D., Associate Professor, Pediatrics; Director, Cardiovascular Genetics; Director, Heart Institute BioRepository, The Heart Institute, Division of Cardiology, Cincinnati Children's Hospital Medical Center

The objective of the Heart Institute BioRepository (HIBR) is to facilitate a broad spectrum of current and future research by combining tissue specimens with deep phenotype information on patients with pediatric heart disease. The HIBR is an ongoing repository using a Human Subjects Research approach. The basic goals of the HIBR are to collect, maintain and govern whole blood, heart tissue and urine, and combine these specimens with a comprehensive phenotype Registry using an Honest Broker system.

3:20 Refreshment Break in the Exhibit Hall with Poster Viewing

4:00 Customized Biobanking in the Era of Precision Medicine – Strategies and Opportunities

Beatrice Knudsen, M.D., Ph.D., Medical Director, Pathology and Laboratory Medicine, Cedars-Sinai Medical Center

We have established an innovative and centralized biobank at Cedars-Sinai Hospital, a 1000-bed tertiary care medical center in Los Angeles. This infrastructure includes a novel approach to consenting patients and a pipeline from tissues to data in a biobank-associated translational research core. The presentation will highlight our strategies, accomplishments and analytical methods development in the endeavor.

4:30 From Many to One: An Initiative to Develop an Institution-Wide Human Specimen Resource at an Academic Medical Center

Devon D. KellyDevon D. Kelly, Director, OHSU Knight BioLibrary, Oregon Health & Science
University, Knight Cancer Institute

OHSU has been collecting and storing specimens for decades. Implementation of a standardized model is necessary to best organize and utilize individually maintained repositories. We will describe our efforts to aggregate multiple repositories under a single umbrella, in areas like governance, community engagement, business modeling, process improvements and informatics platforms, plus change process management strategies, current examples of collaborative relationships and uses of the specimens.

5:00 Governance Model for a Pathology-Based Tissue Procurement Core at the Duke Cancer Institute

Shannon McCallShannon McCall, M.D., Director, Duke Biospecimen Repository and Processing Core, Pathology, Duke University School of Medicine

Duke's Department of Pathology has established a shared resource for tissue procurement: the Biospecimen Repository and Processing Core (BRPC). It operates under one IRB protocol and its "customers" are the DCI's 10 Disease-Specific Working Groups, which each determine priorities for specimen collection and utilization. This governance model reduces not only competition between investigators to enroll patients and collect specimens but also the risk to patients. It supports efficiencies in research expenditures by fostering collaboration, increasing cohort sizes and utilizing biospecimens for multiple downstream analyses.


Science of Supplying
High-Quality Specimens

1:30 pm Chairperson's Opening Remarks

Jay A. Tischfield, Ph.D., CEO, RUCDR Infinite Biologics, Distinguished Professor, Genetics, Rutgers University

1:35 Preventing "Identity Theft" at a Biobank via Analytical and Functional Quality Control

Jay TischfieldJay A. Tischfield, Ph.D., CEO, RUCDR Infinite Biologics, Distinguished Professor, Genetics, Rutgers University

Nucleic acid quality control is essential for accurate and reproducible genomic analysis in both research and clinical settings. However, most sample processing is decentralized, leading to differential results between laboratories. To this end, standardized functional quality control methods have been developed to qualify nucleic acid quality and, most importantly, provide a metric for comparing samples extracted at different sites. The critical need to develop a quality gold standard for nucleic acid and implement best practices in sample management focusing on integrity, quality and control will be discussed.

2:05 Development of a High-Throughput RNA Extraction and Quality Control Process

Victoria KellyVictoria Kelly, Ph.D., Molecular Biology Group Leader, Molecular Biology, Coriell Institute for Medical Research

RNA from whole blood is a common sample type collected in longitudinal clinical research studies, with many of these studies aiming to discover miRNA biomarkers. Developing high-throughput methods by which to extract whole RNA including miRNA and analyze quality while maintaining integrity from sample accession to distribution is critical for the value of these collections. We will present our process including data collected to optimize and validate methods of extraction and quality control testing.

2:35 The SPIN and SMART Metrics: The New Generation of Biorepository Sample Quality Assessment for Downstream Analysis

Timothy J. GeddesTimothy J. Geddes, Manager, Erb Family Core Molecular Laboratory, Beaumont BioBank, William Beaumont Hospital

We describe the development of two metrics designed to keep up with emerging proteomic and genomic analysis technologies. The first of these is known as SPIN (Sample-specific Protein Integrity Number) and is designed to discover proteins in individual sample types with the goal of establishing an index to assess the integrity of stored specimens for protein-based biomarker studies. The second metric is referred to as SMART (Size Metric Analysis RNA Threshold), which is formulated to determine the usability of highly degraded RNA isolated from archived FFPE blocks.

3:05 Selected Oral Poster Presentation: Long-Term Storage of Dry RNA in a Skin Cancer Biorepository for Next-Generation Molecular Studies

Steven Robinson, Ph.D., Research Manager, Skin Cancer Biorepository, Division of Medical Oncology, University of Colorado

High-quality RNA is required for molecular biology experiments. Novel techniques for desiccating and storing RNA at room temperature have recently been developed. In this presentation, we will look at the comparative quality of desiccated versus frozen RNA stored over long periods for use in next-generation molecular studies, including gene expression assays and whole-transcriptome sequencing.

3:20 Refreshment Break in the Exhibit Hall with Poster Viewing

4:00 What We Know about the Influence of Storage Temperature on Biospecimen Quality

Allison HubelAllison Hubel, Ph.D., Professor, Mechanical Engineering and Director, Biopreservation Core Resource, University of Minnesota

Selection of a temperature at which to store your biospecimens can be a daunting task. There are scientific principles for the selection of a storage temperature that can help guide selection. A summary of studies on storage temperature will also be described.

4:30 Appropriate Freezing Processes and Optimal Storage Containers for Biological Specimens

Alexandra Lerch-GagglAlexandra Lerch-Gaggl, Ph.D., Scientific Director, Pediatric BioBank & Analytical
Tissue Core, Children's Research Institute and Medical College of Wisconsin

Best sample quality even after long-term storage should be a priority of sample banking. This presentation will discuss advantages and differences between various freezing techniques, introduce the purpose of using cryoprotective agents, demonstrate differences in storage containers and raise the awareness for factors influencing samples integrity related to freezing and thawing after long-term storage.

5:00 CAP Accreditation for Biorepositories: A New Approach to Biospecimen Quality

Philip BrantonPhilip Branton, M.D., Consulting Pathologist, Biorepositories and Biospecimens Research Branch, National Cancer Institute, National Institutes of Health

CAP Accreditation offers an opportunity for standardization of practice. Today, there are few resources for biobanks that seek external verification/quality assurance of how they are performing and how they are conforming to benchmark standards of quality. The CAP Biorepository Accreditation Program features a unique peer-based inspector model that integrates education and a sharing of best practices to advance quality.

5:30 Welcome Reception in the Exhibit Hall with Poster Viewing

6:30 Close of Session


Day 1 | Day 2 | Day 3 | Biographies 

By Series:
By Region:

& Course Catalog

CHI Catalog 

Short Course DVDs